FDA Delays Decision on Selinexor’s Approval for Heavily Treated Multiple Myeloma
The U.S. Food and Drug Administration is delaying its…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
FDA Application Submitted for Darzalex Combo Therapy to Treat Certain Multiple Myeloma Patients
An application has been submitted seeking U.S. approval of…
FDA Puts Partial Hold on Venetoclax’s Multiple Myeloma Trials
The U.S. Food and Drug Administration (FDA) has placed…
Phase 1/2 Trial of Tinostamustine Recruiting Patients with Myeloma, Other Blood Cancers
The expansion part of a Phase 1/2 clinical trial…
Darzalex Triple Combo Approved in England for Difficult-to-treat Multiple Myeloma
A triple combination of Darzalex (daratumumab), Velcade…
Janssen Seeks Final FDA Approval for Darzalex Combo Therapy for Newly Diagnosed Multiple Myeloma
Janssen has is seeking approval from the U.S. Food and…
